Results 111 to 120 of about 31,546 (239)

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann, Ruy M. Ribeiro, Aurélien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis c: Allo or autoimmune de novo hepatitis?

, 2009
BACKGROUND: The recurrence of hepatitis C after liver transplantation is extremely frequent. Antiviral therapy combining pegylated-interferon with ribavirin is therefore increasingly used in these patients.
ROSSI, MASSIMO, MERLI, Manuela, BIANCO, Paolo, GENTILI, Federica, MENNINI, Gianluca, CORSI, ALESSANDRO, GIUSTO, MICHELA, GINANNI CORRADINI, Stefano, ATTILI, Adolfo Francesco   +8 more
core   +1 more source

Expression of mutant TIE2 p.L914F during mouse development causes embryonic lethality and defects in vascular remodeling

Developmental Dynamics, EarlyView.
Abstract Background Sporadic venous malformation (VM) is associated with the hyperactivating p.L914F mutation in TIE2, a receptor tyrosine kinase essential for vascular development. This mutation is not found in hereditary VM, suggesting incompatibility with life when expressed during early vascular development.
Lindsay J. Bischoff, Sandra Schrenk, Kara Soroko, Chhiring Sherpa, Ashok Arasu, Damien Reynaud, Elisa Boscolo   +6 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

RNA virus modulation of IFN, PI3K and apoptosis

, 2009
Interferon (IFN) and phosphatidylinositol 3-kinase (PI3K) are apoptosis regulators that are targeted by viruses to promote survival of infected cells.
Killip, Marian J.
core  

Development of Pentaplex Reverse Transcription Droplet Digital PCR Assay for Simultaneous Detection and Absolute Quantification of HIV‐1, HIV‐2, HCV, and HBV With Internal Control

ELECTROPHORESIS, EarlyView.
Development of Pentaplex reverse transcription droplet digital PCR assay for simultaneous detection and absolute quantification of HIV‐1, HIV‐2, HCV, and HBV with internal control. The channel‐resolved multiplex strategy enables high sensitivity, robust quantification, and scalable digital PCR workflows across platforms.
Soo Yeon Lim, Un Na Koh, Ah Leum Kim, Yebin Kim, Ga Eun Kim, Si‐Keun Lim   +5 more
wiley   +1 more source

High‐frequency oscillations after acute hemorrhagic traumatic brain injury: insights into posttraumatic epilepsy development

Epilepsia, EarlyView.
Abstract Objective The development of posttraumatic epilepsy after traumatic brain injury (TBI) is potentially identifiable by measuring biomarkers of epileptogenesis, namely pathological high‐frequency oscillations (pHFOs). pHFOs are promising candidates, but it remains uncertain whether they can be detected early after TBI in clinical settings.
Kseniia Kriukova, Lin Li, Richard J. Staba, Misque Boswell, Tuba Asifriyaz, Rachel Thomas, James J. Gugger, Mohamad Shamas, Ramon Diaz‐Arrastia, Manuel Buitrago Blanco, Jerome Engel, Paul M. Vespa, Dominique Duncan, on behalf of the EpiBios4Rx investigators, Denes Agoston, Alicia K. Au, Michael Bell, Ben Churn, Jan Claassen, Ramon Diaz‐Arrastia, Jerome Engel, Brandon Foreman, Aristea Galanopoulou, Emily Gilmore, Martin Hunn, Nathalie Jette, Andrew Morokoff, Solomon L. Moshé, Terence O'Brien, Joshua Laing, Piero Perucca, Kristine H. O'Phelan, Asla Pitkanen, Eric Rosenthal, Frederick Willyerd, Lara Zimmermann, Ben Ellingson, Buitrago Blanco, Daniel Correa, Dana Harrar, Thomas P. Bleck, Brian Appavu, Aaron Struck, Baxter Allen, Inna Keselman, Jeff Kennedy, Victor Ferastraoaru, Ji Yeoun Yoo, Arthur W. Toga   +48 more
wiley   +1 more source

Pulsed Light Technology in Food Safety and Preservation: Principles, Applications, and Future Directions

Food Chemistry International, EarlyView.
Pulsed light technology uses short high‐intensity broad‐spectrum flashes (200–1100 nm) to inactivate microbes via DNA damage. It preserves food quality, extends shelf life, and works on liquids, meats, and produce, often combined with other hurdles for enhanced efficacy.
Abdul Mueez Ahmad, Laiba Younas, Fatima Javed, Rimsha Amjad, Muhammad Tayyab Raza   +4 more
wiley   +1 more source

Prevalença de la infecció pel virus de la hepatitis B i C en pacients amb malaltia inflamatòria intestinal. Impacte del tractament immunosupressor en l’evolució de l’hepatopatia [PDF]

, 2010
INTRODUCCIÓ: Hi ha molt poca informació a la literatura mèdica que suggereix que existeix una alta prevalença de la infecció pel virus hepatitis B (VHB) i C (VHC) en malalts amb malaltia inflamatòria intestinal (MII).
Loras Alastruey, Carme
core  

Evolución post-trasplante hepático y respuesta al tratamiento antiviral en los pacientes con cirrosis de etiología mixta (virus C+alcohol). Comparación en los trasplantados por cirrosis por virus C o cirrosis por alcohol.

, 2007
Evolution after liver transplantation (LT) in mixed cirrhosis (hepatitis C(HCV)+alcohol) is unknown. Moreover, antiviral treatment with pegylatedinterferon+ ribavirin is the only therapy for recurrent hepatitis C and it is unknown if response is ...
Aguilera Sancho-Tello, Mª Victoria
core